Shionogi Completes $2.5 Billion Acquisition of RADICAVA for ALS Treatment, Expanding Rare Disease Portfolio
核心洞察
Shionogi completed the acquisition of global rights to RADICAVA (edaravone) from Tanabe Pharma for $2.5 billion, establishing the company as a commercially viable rare disease player.
RADICAVA, approved for amyotrophic lateral sclerosis (搜索) treatment, has treated over 22,000 ALS (搜索) patients in the U.S. and generates approximately $700 million in annual global sales.
The acquisition includes both oral suspension and intravenous formulations of edaravone, along with an established rare disease team and ALS (搜索) treatment platform.
Shionogi & Co., Ltd. has completed its $2.5 billion acquisition of global rights to RADICAVA (edaravone) from Tanabe Pharma Corporation (搜索), marking a significant expansion into the rare disease market and establishing the Japanese pharmaceutical company as a major player in amyotrophic lateral sclerosis (搜索) (ALS (搜索)) treatment.
The acquisition, finalized on April 2, 2026, includes all intellectual property rights and sales rights for both RADICAVA ORS (oral suspension) and IV RADICAVA (intravenous formulation) in major countries and regions, with additional territories to follow. The transaction adds approximately $700 million in annual global sales and is expected to be immediately accretive in fiscal year 2026.
Strategic Expansion into Rare Disease
"By completing the acquisition of RADICAVA we are demonstrating progress toward our 2030 Vision and fulfilling our commitment to supply the best possible medicines to protect the health and wellbeing of the patients we serve," said Isao Teshirogi, Ph.D., CEO of Shionogi. "With RADICAVA we are not only acquiring a medication, we are also acquiring an established rare disease capability and assuming responsibility for a relationship with the ALS (搜索) community."
The acquisition includes the integration of Tanabe's cross-functional RADICAVA team, providing Shionogi with established rare disease expertise and commercial infrastructure. This represents a strategic investment in Shionogi's broader rare disease franchise, which includes clinical programs in Fragile X syndrome (搜索), Jordan's Syndrome (搜索), and Pompe disease (搜索).
Established ALS Treatment Platform
RADICAVA is approved by the U.S. Food and Drug Administration and other regulatory authorities worldwide for treating ALS (搜索), a progressive neurodegenerative disease with no cure and limited treatment options. The drug has been used to treat more than 22,000 people with ALS in the U.S., accumulating over 2.8 million days of therapy and being prescribed by over 2,800 healthcare professionals.
The oral suspension formulation, RADICAVA ORS, received FDA approval on May 12, 2022, and was granted Orphan Drug Exclusivity in 2024 based on its major contribution to patient care by providing an oral route of administration that avoids the burdens of IV administration. The drug is administered in cycles: 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle, then 10 days within a 14-day period followed by a 14-day drug-free period for subsequent cycles.
Global Market Presence
Edaravone was originally discovered and developed by Tanabe Pharma through a 13-year research program beginning in 2001. The drug first received approval as RADICUT in Japan and South Korea in 2015, followed by marketing authorizations in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), Malaysia (December 2021), Australia (February 2023), and Brazil (February 2024).
Addressing Unmet Medical Need
ALS (搜索) affects approximately 1-2 cases per 100,000 population annually worldwide, making it a rare disease with significant unmet medical need. The progressive neurodegenerative condition is characterized by selective degeneration and loss of motor neurons (搜索), leading to muscle weakness, respiratory impairment, and ultimately respiratory muscle paralysis that severely impacts life expectancy.
"RADICAVA is an important option for people with ALS (搜索) and we are committed to serving the community's needs today and working toward future innovations in care," said Nathan McCutcheon, President and CEO of Shionogi Inc. "We are excited to continue growing our rare disease capabilities with the addition of the talented cross-functional team from Tanabe."
Financial Structure and Future Outlook
To finance the acquisition, Shionogi secured a JPY 360 billion bridge loan from Sumitomo Mitsui Banking Corporation (搜索), with plans to refinance into mid- to long-term financing by the May 2027 repayment deadline. Under the acquisition terms, Shionogi may pay additional royalties on future sales subject to certain conditions.
The transaction establishes Shionogi as a commercially viable rare disease company positioned to introduce new treatments to patients with unmet medical needs, supporting the company's strategic focus on infectious diseases and diseases with unmet medical needs including pain, CNS disorders, Alzheimer's disease (搜索), oncology, rare diseases, and sleep apnea.